UK markets close in 5 hours 47 minutes
  • FTSE 100

    7,485.12
    -4.07 (-0.05%)
     
  • FTSE 250

    18,894.89
    -35.68 (-0.19%)
     
  • AIM

    832.14
    -2.39 (-0.29%)
     
  • GBP/EUR

    1.1578
    -0.0034 (-0.29%)
     
  • GBP/USD

    1.2163
    -0.0042 (-0.35%)
     
  • BTC-GBP

    13,832.02
    -62.53 (-0.45%)
     
  • CMC Crypto 200

    395.17
    -6.86 (-1.71%)
     
  • S&P 500

    3,933.92
    -7.34 (-0.19%)
     
  • DOW

    33,597.92
    +1.58 (+0.00%)
     
  • CRUDE OIL

    72.39
    +0.38 (+0.53%)
     
  • GOLD FUTURES

    1,795.00
    -3.00 (-0.17%)
     
  • NIKKEI 225

    27,574.43
    -111.97 (-0.40%)
     
  • HANG SENG

    19,450.23
    +635.41 (+3.38%)
     
  • DAX

    14,248.26
    -12.93 (-0.09%)
     
  • CAC 40

    6,668.00
    +7.41 (+0.11%)
     

Head And Neck Cancer Therapeutics Market Is Estimated To Grow At CAGR Of 8.5 %, 2022-2028 | Latest Industry Coverage By Douglas Insights

Douglas Insights
Douglas Insights

The industry-leading players include Bristol-Myers, Sanofi S.A., Pfizer Inc, Merck & Co, and AstraZeneca plc. As the market is expected to grow in the coming years, industry players can use the Douglas Insights comparison engine to extract valuable insights and use the information to make the best investment decisions and marketing strategies.

Isle Of Man, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Douglas Insights has made the newest addition to their comparison engine. Head and neck cancer therapeutics market research reports can now be compared and evaluated on the world’s first comparison engine to gain quality insights. Using the comparison engine, analysts, researchers, and professionals can evaluate reports by publisher rating, number of pages, table of contents, and pricing. These evaluations and comparisons are crucial for understanding the market, like changing industry trends, growth drivers, constraints, challenges, and opportunities.

Including research reports on the global head and neck cancer therapeutics market in the comparison engine, Douglas Insights truly provides users the perfect opportunity to efficiently gather qualitative and quantitative data. Furthermore, access to quality insights and valuable data from global research will help industry players develop growth strategies and make informed decisions to capture bigger market share or enter new markets. Simply stated, access to crucial data will open the world of opportunities for industry players.

Compare the report and make your decision - https://douglasinsights.com/head-and-neck-cancer-therapeutics-market

Market Drivers

The forecast from 2022 to 2027 shows that the head and neck cancer therapeutics industry’s CAGR (compound annual growth rate) is expected to increase by 8.5 percent. Unfortunately, the prevalence of cancer is at an all-time high. Cases of neck and head cancers are also increasing, including numerous types of malignant tumors that develop around the throat, salivary glands, mouth, sinuses, nose, and larynx.

The increasing number of cancer cases has soared the demand for therapeutics (devices and drugs). This demand has further led many organizations to invest in research and development activities. Through R&D, organizations are expected to introduce effective and innovative solutions to manage cases and treat patients. And that is further expected to drive the market growth.

Besides this, technological breakthroughs in cancer screening processes and the strong presence of cancer drugs in the pipeline, like Ipilimumab, Avelumab, Afatinib, and Bevacizumab, will act as the market growth drivers in the forecast timeline. Another growth factor is the skyrocketing increase in the risk factors that can result in cancer. These include smoking, high consumption of tobacco and alcohol among people worldwide, and lack of physical activity.

Though the global head and neck cancer therapeutics market is dominated by North America, including the United States and Canada, Asia-Pacific may take the lead. The region presents the most lucrative opportunities for industry players to grow their market share. The top reason is the ticking number of risk factors. Apart from the high usage of tobacco and consumption of alcohol, chewing betel quid is also quite common in Asia-Pacific. These risk factors have surged the number of cases and made Asia-Pacific the growing hub for cancer patients.

Inarguably, the head and neck cancer therapeutics market is progressing upward. The market is segmented into drugs, surgeries, radiation therapy, chemotherapy, and immunotherapy. Industry players across the globe are vested in getting valuable findings through research and analysis. This research enables them to take the best steps and decisions to introduce effective solutions to the market so that patients can get diagnosed early and seek treatment fast, increasing their chances of recovery and enjoying quality living.

Key players

The industry-leading players include Bristol-Myers, Sanofi S.A., Pfizer Inc, Merck & Co, and AstraZeneca plc. As the market is expected to grow in the coming years, industry players can use the Douglas Insights comparison engine to extract valuable insights and use the information to make the best investment decisions and marketing strategies. Informed decision-making will help generate high investment returns, increase market share and penetrate new markets.

Set a budget for a custom project and see offers from publishers all over the world- https://douglasinsights.com/projects

Head and neck cancer therapeutics Market Report Coverage

Report Attributes

Details

Market Size in 2021

$XXBN

Market Size Projection in 2028

$XX BN

CAGR (2021-2028)

 8.3%

Largest Market

North America

Growth Drivers

Increasing number of cancer cases, technological breakthroughs in cancer screening processes, strong presence of cancer drugs in the pipeline, like Ipilimumab, Avelumab, Afatinib, and Bevacizumab

Segmentation

By Diagnostic Method (Diagnostic Methods, Biopsy, Imaging, Endoscopy, Other Diagnostic Methods) by Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy) by Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer) by Route of Administration (Injectable, Oral) by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors) by End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

Regional Analysis

North America (US, Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Europe (U.K, Germany, Italy, France, Spain, Russia and Rest of Europe), APAC (China, Japan, India, South Korea, Australia, ASEAN and Rest of Asia Pacific), ME (GCC Countries, Israel, and Rest of Middle East) & Africa (South Africa, North Africa and Central Africa)

Key Companies Covered

Bristol-Myers, Sanofi S.A., Pfizer Inc, Merck & Co, and AstraZeneca plc

Segmentations

By Diagnostic Method

  • Diagnostic Methods,

  • Biopsy,

  • Imaging,

  • Endoscopy,

  • Other Diagnostic Methods

By Treatment Type

  • Surgery,

  • Radiation Therapy,

  • Chemotherapy,

  • Immunotherapy,

  • Targeted Therapy

By Disease Indication

  • Lip and Oral Cavity Cancer,

  • Laryngeal Cancer,

  • Oropharyngeal Cancer,

  • Salivary Gland Cancer,

  • Nasopharyngeal Cancer,

  • Hypopharyngeal Cancer

By Route of Administration

  • Injectable,

  • Oral

By Therapeutic Class

  • PD Inhibitors,

  • EGFR Inhibitors,

  • Microtubule Inhibitors

By End User

  • Hospitals,

  • Specialty Clinics,

  • Ambulatory Surgical Centers,

  • Others

Key questions answered in this report

  • COVID 19 impact analysis on global Head and neck cancer therapeutics industry.

  • What are the current market trends and dynamics in the Head and neck cancer therapeutics market and valuable opportunities for emerging players?

  • What is driving Head and neck cancer therapeutics market?

  • What are the key challenges to market growth?

  • Which segment accounts for the fastest CAGR during the forecast period?

  • Which product type segment holds a larger mark et share and why?

  • Are low and middle-income economies investing in the Head and neck cancer therapeutics market?

  • Key growth pockets on the basis of regions, types, applications, and end-users

  • What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Unique data points of this report

  • Statistics on Head and neck cancer therapeutics and spending worldwide

  • Recent trends across different regions in terms of adoption of Head and neck cancer therapeutics across industries

  • Notable developments going on in the industry

  • Attractive investment proposition for segments as well as geography

  • Comparative scenario for all the segments for years 2018 (actual) and 2028 (forecast)

Table of Content:

Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Scope of Report
1.3 Methodology and Information Sources
1.4 Geographic Breakdown
1.5 Analyst's Credentials
1.6 BCC Custom Research
1.7 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background
3.1 Head and Neck Cancer Overview
3.2 Incidence
3.3 Stages of Head and Neck Cancer
3.4 Risk Factors
3.4.1 Alcohol and Tobacco Usage
3.4.2 Occupational Exposure
3.4.3 Radiation Exposure
3.4.4 Gender
3.4.5 Human Papillomavirus Infection (HPV)
3.5 Symptoms
3.6 Blockbuster Drugs
3.6.1 Erbitux (Cetuximab)
3.6.2 Taxotere (Docetaxel)
3.6.3 Keytruda (Pembrolizumab)
3.6.4 Opdivo (Nivolumab)
3.6.5 Hydrea (Hydroxyurea)

Chapter 4 Regulatory Structure
4.1 Regulatory Challenges for Selected Countries
4.1.1 United States
4.1.2 Canada
4.1.3 Europe
4.1.4 Japan
4.1.5 India
4.1.6 Brazil

Chapter 5 Market Breakdown, by Diagnostic Method
5.1 Diagnostic Methods
5.1.1 Biopsy
5.1.2 Imaging
5.1.3 Endoscopy
5.1.4 Other Diagnostic Methods

Chapter 6 Market Breakdown, by Treatment Type
6.1 Overview
6.2 Treatment Types
6.2.1 Surgery
6.2.2 Radiation Therapy
6.2.3 Chemotherapy
6.2.4 Immunotherapy
6.2.5 Targeted Therapy

Chapter 7 Market Breakdown, by Disease Indication
7.1 Overview
7.2 Disease Indications
7.2.1 Lip and Oral Cavity Cancer
7.2.2 Laryngeal Cancer
7.2.3 Oropharyngeal Cancer
7.2.4 Salivary Gland Cancer
7.2.5 Nasopharyngeal Cancer
7.2.6 Hypopharyngeal Cancer

Chapter 8 Market Breakdown, by Route of Administration
8.1 Overview
8.2 Route of Administration
8.2.1 Injectable
8.2.2 Oral

Chapter 9 Market Breakdown, by Therapeutic Class
9.1 Overview
9.2 Therapeutic Classes
9.2.1 PD Inhibitors
9.2.2 EGFR Inhibitors
9.2.3 Microtubule Inhibitors

……………..continued

Compare the report and make your decision : https://douglasinsights.com/head-and-neck-cancer-therapeutics-market

Inquire Before Buying This Research Report: https://douglasinsights.com/static/contact-us

Follow Douglas Insights For More Industry Updates- @ LinkedIn Twitter

About Douglas Insights-

Douglas Insights UK limited is the first company to provide comparison of market research reports by Table of content, price, ratings and number of pages. We understand the value of time. Productivity and efficiency are possible when you take prompt and assured decisions. With our advanced algorithm, filters, and comparison engine, you can compare your preferred reports simultaneously, based on publisher rating, published date, price, and list of tables. Our data portal enables you to find and review the reports from several publishers. You can evaluate numerous reports on the same screen and select the sample for your best match.

Similar Market Research Report Comparisons:

Cancer Treatment Market: Cancer is a disease in which some of the body's cells grow uncontrollably and eventually spread to other parts of the body. The cancerous tumor spreads to nearby tissues and can travel to distant places within the body to form a new tumor.

Breast Cancer Treatment Market: This report on global breast cancer treatment market studies various drugs used for treatment of breast cancer along with pipeline analysis of upcoming potential drugs. Breast cancer is the second most common cancer observed in women worldwide, accounting for around 17% of all female cancers, making the disease exceptionally prevalent.

Cancer Biomarkers Market: Global Cancer Biomarkers Market is valued at approximately at USD 10.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 11.8% over the forecast period 2020-2027.

Gastric Cancer Drugs Market: Colombia gastric cancer drugs market is projected to register a substantial CAGR of 8.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

CONTACT: Office- Bridge House, W Baldwin Rd, Isle of Man IM4 5HA, Isle of Man Email- isabella@douglasinsights.com Telephone - +44 7624 248772 Web- douglasinsights.com/